Head-to-head evidence
LB54640 vs setmelanotide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: MC4R · full Obesity pipeline
LB54640
Developed by Rhythm Pharmaceuticals and partners
NCT06046443 · Phase 2 · completed
This was a randomized, triple-blind, placebo-controlled Phase 2 trial in 28 participants with hypothalamic obesity. All three LB54640 doses produced a statistically significant reduction in BMI at 14 weeks compared with placebo, for example the highest dose: -9.3% vs +2.2% with placebo, p=0.0004, meeting the trial primary comparison, though the very small number of participants limits how confidently this result generalizes.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
setmelanotide · Imcivree
Marketed by Rhythm Pharmaceuticals
NCT02896192 · Phase 3 · completed
The study was an open-label, single-group trial of 15 participants; although it included a short double-blind placebo-withdrawal period, the primary one-year weight-loss endpoint was assessed without a parallel placebo or active-control arm. The primary endpoint was statistically positive against a predefined 5% benchmark, but the uncontrolled design limits the strength of evidence.
Next expected readout: October 2026 · NCT06772597 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LB54640's landscape · setmelanotide's landscape